← All memosResearch · MEMO-006Neuroprotection and regeneration: the state of the field, 2026Published15 Nov 2026Reading time6 minVersion1.0StatusWorking noteSummaryPartial epigenetic reprogramming enters human trials; nicotinamide in Phase III; stem-cell replacement remains preclinical.FULL MEMO IN PREPARATION